Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1510 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Sneha A Dongre und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, BioGenomics Ltd, Maharashtra, India. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Hypoglycemic Agents, Insulin Aspart. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Insulin aspart, a rapid‐acting analog, achieves faster subcutaneous absorption than regular insulin. This study aimed to demonstrate equivalence in the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of Recombinant Human Insulin Aspart from BioGenomics Limited (as test) and Novo‐Nordisk (as reference) in healthy adult males. This was a double‐blind, randomized, cross‐over study, assessing PK and PD parameters under fasting conditions. Participants received either 0.2 U/kg of test or reference product via a subcutaneous route in the abdominal area. PK parameters included maximum serum concentration (C max ), area under the curve [(AUC [0‐t] ) and (AUC [0‐∞] )], time to maximum serum concentration (T max ), and half‐life (t ½ ). PD parameters included amount of glucose infused (G tot ), maximum glucose infusion rate (R max ), time of R max (tR max ), late time of half‐maximal glucose infusion rate (tR max50 ), time of first measured glucose infusion rate (t onset ), and cessation of glucose infusion/clamp (tR last ). Seventy subjects between 18 and 45 years of age and body mass index between 18 and 27 kg/m 2 were enrolled. The 90% confidence intervals (CIs) for C max , AUC [0‐t] , AUC [0‐∞] for insulin, and the 95% CIs for G tot , R max for glucose were within 80%‐125% as required to assess test‐reference bioequivalence. No serious adverse events were observed. Both the preparations showed bioequivalence under fasting conditions with a similar safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, BioGenomics Ltd, Maharashtra, India.
- Molecular Biology Department, BioGenomics Ltd, Maharashtra, India.
- Analytical Development, BioGenomics Ltd, Maharashtra, India.
- Downstream and Purification Department, BioGenomics Ltd, Maharashtra, India.
- VEEDA Clinical Research Ltd, Gujarat, India.
- Clinical Affairs Department, VEEDA Clinical Research Ltd, Gujarat, India.
Zitieren
APA
Dongre, S. A., Kulkarni, G. A., Thapa, D., Ghade, N., Lona, J., Prajapati, H., Mehta, H., Guttikar, S., Krishnan, A. R., & Sonar, S. M. (2025). Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1510
Vancouver
Dongre SA, Kulkarni GA, Thapa D, Ghade N, Lona J, Prajapati H, et al. Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1510
BibTeX
@article{Dongre2025,
author = {Dongre, Sneha A and Kulkarni, Gauri A and Thapa, Damodar and Ghade, Nikhil and Lona, Jeseena and Prajapati, Hiren and Mehta, Hiren and Guttikar, Swati and Krishnan, Archana R and Sonar, Sanjay M},
title = {Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1510}
}
EUVIMED